3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
8
Recruiting
5
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
44
Breast Neoplasms
33
Neoplasms
31
Melanoma
24
Neoplasm Metastasis
22
Leukemia, Myeloid, Acute
21
Colorectal Neoplasms
18
Prostatic Neoplasms
17
Multiple Myeloma
17
Lung Neoplasms
17
Ovarian Neoplasms
14
Myelodysplastic Syndromes
13
Squamous Cell Carcinoma of Head and Neck
12
Recurrence
12
Lymphoma, Non-Hodgkin
12
Carcinoma, Renal Cell
11
Uterine Cervical Neoplasms
10
Urinary Bladder Neoplasms
10
Pancreatic Neoplasms
10
Lymphoma, Large B-Cell, Diffuse
10
Glioblastoma
10
Brain Neoplasms
10
Carcinoma, Hepatocellular
9
Stomach Neoplasms
8
Triple Negative Breast Neoplasms
7
Rectal Neoplasms
7
Lymphoma
7
Hodgkin Disease
7
Head and Neck Neoplasms
7
Glioma
7
Interventions
pembrolizumab
1
enfortumab vedotin
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Urethral Neoplasms
×
90 days
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA